July 2022
-
Media ReleaseApplications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMASubmission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU Multiple sclerosis (MS) is a chronic…
-
Media ReleaseSandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with…
-
Media ReleaseNovartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidanceAd hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33%…
June 2022
-
Media ReleaseSandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMASubmission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced…
-
Media ReleaseHEXAL launches Dimethyl fumarate HEXAL® a generic drug for Tecfidera®, in Germany, offering an economically efficient treatment option for the care of adult patients with multiple sclerosis*Dimethyl fumarate HEXAL® is bioequivalent to the originator product 1,2,3 Additional 196 pack size reduces co-payment burden for patients Basel, June 10, 2022 — Sandoz expands its portfolio and…
May 2022
-
Media ReleaseSandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide…
-
Media ReleaseSandoz appoints new Board representative to global AMR Industry AllianceDr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA) The Alliance brings together about 100 life…
-
Media ReleaseSandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolioPirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2 Approximately 140,000 Americans…
April 2022
-
Media ReleaseNovartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlookAd hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating…
-
Media ReleaseSandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolioBrimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does…